… hemolysis. Using the recently described modified Ham test with serum from patients with
atypical hemolytic uremic syndrome, … potential utility for this disease of alternative pathway of …

First described by Gasser and colleagues 1 in 1955, hemolytic uremic syndrome (HUS) is
the clinical triad of thrombocytopenia, anemia, and acute kidney injury. It is classically …

… A linear mixed effects model was used with random effects for each pt … monitored off Ecu
and prompt reinitiation of treatment on recurrence could be efficient in controlling the disease. …

… plays a role in the pathogenesis of atypical hemolytic uremic syndrome (aHUS), a thrombotic
… for repeated testing was disease monitoring or therapy efficacy monitoring (ie, eculizumab). …

… complement inhibitor treating atypical hemolytic uremic syndrome (aHUS… model compared
direct medical costs (including treatment, administration, monitoring and relapse management…

… of complement inhibition therapy in atypical hemolytic uremic syndrome [abstract]. Blood.
2020;… National observational study monitoring the restrictive regimen of eculizumab therapy in …

… treatment for at least 3 to 6 months and achieved maximal kidney function recovery before
inclusion. They were closely monitored after treatment … >18 months after treatment cessation. …

… and personalize treatments, it is necessary that population pharmacokinetic models or …
Optimization of eculizumab dosing based on the monitoring of pharmacokinetics can only …

… Atypical hemolytic uremic syndrome (aHUS) is a complement system (CS)–mediated ultrarare
disease … There is no gold standard test to monitor disease activity; however, the ex vivo …

… INTRODUCTION: Atypical hemolytic uremic syndrome (aHUS) is a rare disease caused
by dysregulation of the alternative complement pathway leading to renal and other ends-organ …